Detection of chromosome 17 aneuplody and TP53 gene deletion in a broad variety of solid tumors by dual-color fluorescence in situ hybridization (FISH)
Keywords:
Aneuploidy, chromosome deletion, genes, p53, in situ hybridization, fluorescence, neoplasms, chromosomal instability, genetic heterogeneity
Abstract
Introduction. TP53 is a tumor suppressor gene located on chromosome 17p13.1. This gene is essential for the control of cell cycle and has been found altered in about 50% of all tumor types.Objective. The presence of aneuploidy of chromosome 17 and TP53 gene deletion at 17p13.1 locus was determined in primary solid tumors using the dual-color FISH (fluorescence in situ hybridization).
Materials and methods. Thirty-eight samples consisted of several types of primary solid tumors. All samples were mechanically and enzymatically disaggregated with 0.2% collagenase prior to obtaining interphase nuclei. The dual-color FISH was performed using direct fluorescent labeling probes for the chromosome 17 centromere (green signal) and for the TP53 gene locus-specific (orange signal).
Results. Characteristic aneuploidy on chromosome 17 was found in 63% (24/38) of the samples. Monosomy occurred most frequently (75%, 18/24), followed by trisomy (17%, 4/24); nullisomy and tetrasomy were less frequent. TP53 gene deletion was found in 89.5% (34/38) of cases. Only four tumors were normal for copy number of chromosome 17 and TP53 gene. The histopathologic study showed that most of the samples were malignant tumors.
Conclusions. Aneuploidy of chromosome 17 and deletion at 17p13.1 locus of TP53 gene were genetic alterations found to be very frequent in solid tumors. The dual-color FISH was able to detect both numerical and structural chromosomal abnormalities in interphase nuclei.
Downloads
Download data is not yet available.
References
1. Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358:502-11.
2. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34:369-76.
3. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol. 2006;18:658-67.
4. Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med. 2008;359:722-34.
5. Duesberg P, Li R, Fabarius A, Hehlmann R. Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006;13:16-44.
6. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA. 1998;95:13692-7.
7. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene. 2007;26:2212-9.
8. Herrera JC, Vásquez G, Ramírez JL, Muñetón CM. Papel del gen TP53 en la oncogénesis. Salud UIS. 2004;26:88-99.
9. Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009; 16:1-12.
10. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157-65.
11. Ramírez GC, Herrera JC, Muñetón CM, Márquez JR, Isaza LF. Análisis de las aneuploidías del cromosoma 17 y deleción del gen TP53 en tumores gastrointestinales por FISH-bicolor. Rev Col Gastroenterol. 2008;23:333-42.
12. Herrera JC, Ramírez GC, Muñetón CM. Estudio de las aneuploidías del cromosoma 17 y la deleción del gen TP53 en neoplasias hematológicas, por la técnica del FISH-bicolor. Iatreia. 2008;21:364-74.
13. Levsky JM, Singer RH. Fluorescence in situ hybridization: past, present and future. J Cell ScI. 2003;116:2833-8.
14. James L, Varley J. Advances in cytogenetic analysis of solid tumours. Cromosome Res. 1996:4:479-85.
15. Rao PH, Mathew S, Lauwers G, Rodríguez E, Kelsen DP, Chaganti RS. Interphase cytogenetics of gastric and esophageal adenocarcinomas. Diagn Mol Pathol. 1993;2:264-8.
16. Kawai T, Hiroi S, Nakanishi K, Sakurai Y, Torikata C. Abnormalities in chromosome 17and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int. 2004;54:413-9.
17. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-14.
18. Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, et al. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab. 2008;93:177-81.
19. Bergamo NA, da Silva Veiga LC, dos Reis PP, Nishimoto IN, Magrin J, Kowalski LP, et al. Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clin Cancer Res. 2005;11:621-31.
20. Fringes B, Mayhew TM, Reith A, Gates J, Ward DC. Numerical aberrations of chromosomes 1 and 17 correlate with tumor site in human gastric carcinoma of the diffuse and intestinal types. Fluorescence in situ hybridization analysis on gastric biopsies. Lab Invest. 2000;80:1501-8.
21. Hes O, Síma R, Nemcová J, Hora M, Bulimbasic S, Kazakov DV, et al. End-stage kidney disease: gains of chromosomes 7 and 17 and loss of Y chromosome in non-neoplastic tissue. Virchows Arch. 2008;453:313-9.
22. Hardisson D, Álvarez-Marcos C, Salas-Bustamante A, Alonso-Guervós M, Sastre N, Sampedro A. Numerical aberrations of chromosomes 8, 9, 11, and 17 in squamous cell carcinoma of the pharynx and larynx: a fluorescence in situ hybridization and DNA flow cytometric analysis of 50 cases. Oral Oncol. 2004;40:409-17.
23. Gallucci M, Guadagni F, Marzano R, Leonardo C, Merola R, Sentinelli S, et al. Status of the p53, p16, RB1 and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol. 2005;58:367-71.
24. Gotte K, Schafer C, Riedel F, Arens N, Hormann K. Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH. Oncol Rep. 2004;11:17-23.
25. Risio M, Casorzoa L, Chiecchioa L, De Rosaa G, Rossinib F. Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genet Cytogenet. 2003;147:44-9.
26. Gomyo Y, Osaki M, Kaibara N, Ito H. Numerical aberrations and point mutation of p53 gene in human gastric intestinal metaplasia and well-differenciated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer. 1996;66:594-9.
27. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: Gustar Fischer, Jena; 1914. p. 1-64.
28. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A, et al. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 2000;119:83-93.
29. Li L, McCormack AA, Nicholson JM, Fabarius A, Hehlmann R, Sachs RK, et al. Cancer-causing karyotypes: chromosomal equilibria between stabilizing aneuploidy and stabilizing selection for oncogenic function. Cancer Genet Cytogenet. 2009;188:1-25.
30. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773-85.
31. Michor F. Chromosomal instability and human cancer. Philos Trans R Soc Lond B Biol Sci. 2005;360:631-5.
32. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-7.
33. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, et al. Analysis of EGFR, HER, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8:363-72.
34. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Pérez EA, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10:267-77.
35. Takahasi Y, Nagata T, Asai S, Shintaku K, Eguchi T, Ishi Y, et al. Detection aberrations on 17p and gene in gastrointestinal cancers by dual (two-color) fluorescence in situ hybridization and GeneChip p53 assay. Cancer Genet Cytogenet. 2000;121:38-43.
36. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627-36.
37. Cesar AC, Borim AA, Caetano A, Cury PM, Silva AE. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet Cytogenet. 2004;153:127-32.
38. Veiga L, Bérgamo N, Kowalski L, Rogatto S. Classical and molecular cytogenetic analysis in head and neck squamous cell carcinomas. Genet Mol Biol. 2003;26:121-8.
39. Nahi H, Lehmann S, Bengtzen S, Jansson M, Möllgård L, Paul C, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma. 2008;49:508-16.
40. Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, Goldblum JR, et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004;17:588-96.
41. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157-62.42. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-9.
43. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834-42.
44. Nowak MA, Michor F, Iwasa Y. Genetic instability and clonal expansion. J Theor Biol. 2006;241:26-32.
45. Yoshimura A, Sugihara H, Ling ZQ, Peng DF, Mukaisho K, Fujiyama Y, et al. How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: analyses of intratumoral heterogeneity in deletion and mutation of TP53. Pathobiology. 2006;73:40-9.
46. Aguilera A, Gómez-González B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008;9:204-17.
47. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99-115.
48. Montenegro Y, Ramírez-Castro JL , Isaza LF, Bedoya G, Muñetón-Peña CM. Análisis genético en pacientes con cáncer colorrectal. Rev Med Chil. 2006;134:1221-9.
49. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784-91.
2. Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34:369-76.
3. Weaver BA, Cleveland DW. Does aneuploidy cause cancer? Curr Opin Cell Biol. 2006;18:658-67.
4. Fröhling S, Döhner H. Chromosomal abnormalities in cancer. N Engl J Med. 2008;359:722-34.
5. Duesberg P, Li R, Fabarius A, Hehlmann R. Aneuploidy and cancer: from correlation to causation. Contrib Microbiol. 2006;13:16-44.
6. Duesberg P, Rausch C, Rasnick D, Hehlmann R. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA. 1998;95:13692-7.
7. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: an oncogenic transcription factor. Oncogene. 2007;26:2212-9.
8. Herrera JC, Vásquez G, Ramírez JL, Muñetón CM. Papel del gen TP53 en la oncogénesis. Salud UIS. 2004;26:88-99.
9. Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009; 16:1-12.
10. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157-65.
11. Ramírez GC, Herrera JC, Muñetón CM, Márquez JR, Isaza LF. Análisis de las aneuploidías del cromosoma 17 y deleción del gen TP53 en tumores gastrointestinales por FISH-bicolor. Rev Col Gastroenterol. 2008;23:333-42.
12. Herrera JC, Ramírez GC, Muñetón CM. Estudio de las aneuploidías del cromosoma 17 y la deleción del gen TP53 en neoplasias hematológicas, por la técnica del FISH-bicolor. Iatreia. 2008;21:364-74.
13. Levsky JM, Singer RH. Fluorescence in situ hybridization: past, present and future. J Cell ScI. 2003;116:2833-8.
14. James L, Varley J. Advances in cytogenetic analysis of solid tumours. Cromosome Res. 1996:4:479-85.
15. Rao PH, Mathew S, Lauwers G, Rodríguez E, Kelsen DP, Chaganti RS. Interphase cytogenetics of gastric and esophageal adenocarcinomas. Diagn Mol Pathol. 1993;2:264-8.
16. Kawai T, Hiroi S, Nakanishi K, Sakurai Y, Torikata C. Abnormalities in chromosome 17and p53 in lung carcinoma cells detected by fluorescence in situ hybridization. Pathol Int. 2004;54:413-9.
17. Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109-14.
18. Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, et al. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab. 2008;93:177-81.
19. Bergamo NA, da Silva Veiga LC, dos Reis PP, Nishimoto IN, Magrin J, Kowalski LP, et al. Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clin Cancer Res. 2005;11:621-31.
20. Fringes B, Mayhew TM, Reith A, Gates J, Ward DC. Numerical aberrations of chromosomes 1 and 17 correlate with tumor site in human gastric carcinoma of the diffuse and intestinal types. Fluorescence in situ hybridization analysis on gastric biopsies. Lab Invest. 2000;80:1501-8.
21. Hes O, Síma R, Nemcová J, Hora M, Bulimbasic S, Kazakov DV, et al. End-stage kidney disease: gains of chromosomes 7 and 17 and loss of Y chromosome in non-neoplastic tissue. Virchows Arch. 2008;453:313-9.
22. Hardisson D, Álvarez-Marcos C, Salas-Bustamante A, Alonso-Guervós M, Sastre N, Sampedro A. Numerical aberrations of chromosomes 8, 9, 11, and 17 in squamous cell carcinoma of the pharynx and larynx: a fluorescence in situ hybridization and DNA flow cytometric analysis of 50 cases. Oral Oncol. 2004;40:409-17.
23. Gallucci M, Guadagni F, Marzano R, Leonardo C, Merola R, Sentinelli S, et al. Status of the p53, p16, RB1 and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol. 2005;58:367-71.
24. Gotte K, Schafer C, Riedel F, Arens N, Hormann K. Intratumoral genomic heterogeneity in primary head and neck cancer and corresponding metastases detected by dual-FISH. Oncol Rep. 2004;11:17-23.
25. Risio M, Casorzoa L, Chiecchioa L, De Rosaa G, Rossinib F. Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genet Cytogenet. 2003;147:44-9.
26. Gomyo Y, Osaki M, Kaibara N, Ito H. Numerical aberrations and point mutation of p53 gene in human gastric intestinal metaplasia and well-differenciated adenocarcinoma: analysis by fluorescence in situ hybridization (FISH) and PCR-SSCP. Int J Cancer. 1996;66:594-9.
27. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: Gustar Fischer, Jena; 1914. p. 1-64.
28. Duesberg P, Li R, Rasnick D, Rausch C, Willer A, Kraemer A, et al. Aneuploidy precedes and segregates with chemical carcinogenesis. Cancer Genet Cytogenet. 2000;119:83-93.
29. Li L, McCormack AA, Nicholson JM, Fabarius A, Hehlmann R, Sachs RK, et al. Cancer-causing karyotypes: chromosomal equilibria between stabilizing aneuploidy and stabilizing selection for oncogenic function. Cancer Genet Cytogenet. 2009;188:1-25.
30. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773-85.
31. Michor F. Chromosomal instability and human cancer. Philos Trans R Soc Lond B Biol Sci. 2005;360:631-5.
32. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623-7.
33. Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, et al. Analysis of EGFR, HER, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8:363-72.
34. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Pérez EA, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009;10:267-77.
35. Takahasi Y, Nagata T, Asai S, Shintaku K, Eguchi T, Ishi Y, et al. Detection aberrations on 17p and gene in gastrointestinal cancers by dual (two-color) fluorescence in situ hybridization and GeneChip p53 assay. Cancer Genet Cytogenet. 2000;121:38-43.
36. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627-36.
37. Cesar AC, Borim AA, Caetano A, Cury PM, Silva AE. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet Cytogenet. 2004;153:127-32.
38. Veiga L, Bérgamo N, Kowalski L, Rogatto S. Classical and molecular cytogenetic analysis in head and neck squamous cell carcinomas. Genet Mol Biol. 2003;26:121-8.
39. Nahi H, Lehmann S, Bengtzen S, Jansson M, Möllgård L, Paul C, et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma. 2008;49:508-16.
40. Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, Goldblum JR, et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol. 2004;17:588-96.
41. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157-62.42. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-9.
43. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun. 2005;331:834-42.
44. Nowak MA, Michor F, Iwasa Y. Genetic instability and clonal expansion. J Theor Biol. 2006;241:26-32.
45. Yoshimura A, Sugihara H, Ling ZQ, Peng DF, Mukaisho K, Fujiyama Y, et al. How wild-type TP53 is inactivated in undifferentiated-type gastric carcinomas: analyses of intratumoral heterogeneity in deletion and mutation of TP53. Pathobiology. 2006;73:40-9.
46. Aguilera A, Gómez-González B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008;9:204-17.
47. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008;266:99-115.
48. Montenegro Y, Ramírez-Castro JL , Isaza LF, Bedoya G, Muñetón-Peña CM. Análisis genético en pacientes con cáncer colorrectal. Rev Med Chil. 2006;134:1221-9.
49. Worthley DL, Whitehall VL, Spring KJ, Leggett BA. Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol. 2007;13:3784-91.
How to Cite
1.
Herrera JC, Isaza LF, Ramírez JL, Vásquez G, Muñetón CM. Detection of chromosome 17 aneuplody and TP53 gene deletion in a broad variety of solid tumors by dual-color fluorescence in situ hybridization (FISH). biomedica [Internet]. 2010 Sep. 30 [cited 2024 Jun. 30];30(3):390-40. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/273
Some similar items:
- Jennyfer Benavides , Jonh Suárez, Ana Estrada, Mábel Bohórquez, Carolina Ramírez, Justo Olaya , Yesid Sánchez , Gilbert Mateus , Luis Carvajal , María Magdalena Echeverry , Breast cancer in six families from Tolima and Huila: BRCA1 3450del4 mutation , Biomedica: Vol. 40 No. 1 (2020)
- María Carolina Sanabria, Gerardo Muñoz, Clara Inés Vargas, Mutations in the BRCA1 gene (185delAG and 5382insC) are not present in any of the 30 breast cancer patients analyzed from eastern Colombia , Biomedica: Vol. 29 No. 1 (2009)
- Oscar F. Herrán, María F. Ardila, Martha P. Rojas, Gustavo A. Hernández, Design of dietary questionnaires to study the relationships between diet and cancer prevalence in Colombia , Biomedica: Vol. 30 No. 1 (2010)
- María Imaz, Sonia Allassia, Mónica Aranibar, Alba Gunia, Susana Poggi, Ana Togneri, Lidia Wolff, Group of Implementation of Fluorescence, Performance of LED fluorescence microscopy for the detection of acid-fast bacilli from respiratory samples in peripheral laboratories in Argentina , Biomedica: Vol. 37 No. 2 (2017)
- Brian Alejandro Suárez, Claudia Liliana Cuervo, Concepción Judith Puerta, The intergenic region of the histone h2a gene supports two major lineages of Trypanosoma rangeli , Biomedica: Vol. 27 No. 3 (2007)
- Patricia Escandón, Popchai Ngamskulrungroj, Wieland Meyer, Elizabeth Castañeda, In vitro mating of Colombian isolates of the Cryptococcus neoformans species complex , Biomedica: Vol. 27 No. 2 (2007)
- Winston Rojas, Maria Antonieta Caro, Juan Guillermo Lopera, Omar Triana, Juan Carlos Dib, Gabriel Bedoya, Analysis of polymorphisms in the trypanothione reductase and cruzipain genes in Colombian strains of Trypanosoma cruzi , Biomedica: Vol. 27 No. 1esp (2007): Enfermedad de Chagas
- Martha Lucía Serrano, Juan José Yunis, Identification of three new mutations in the RB1 gene in patients with sporadic retinoblastoma in Colombia , Biomedica: Vol. 33 No. 1 (2013)
- Ricardo Cendales, Constanza Pardo, Claudia Uribe, Guillermo López, María Clara Yépez, Luis Eduardo Bravo, Data quality at population-based cancer registries in Colombia , Biomedica: Vol. 32 No. 4 (2012)
- Andrea Gómez, Gustavo Salguero, Herbert García, Fabio Aristizábal, Oscar Gutiérrez, Luis Alberto Angel, Jorge Padrón, Carlos Martínez, Humberto Martínez, Omar Malaver, Rosa Barvo, Alejandro Giraldo, Detection mutations in the DNA mismatch repair genes of hMLH1 and hMSH2 genes in Colombian families with suspicion of hereditary non-polyposis colorectal carcinoma (Lynch syndrome). , Biomedica: Vol. 25 No. 3 (2005)
Published
2010-09-30
Issue
Section
Original articles
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |